Travere Therapeutics (TVTX) Total Liabilities (2011 - 2026)
Travere Therapeutics' (TVTX) quarterly Total Liabilities came in at $456.5 million in Q1 2026, down 11.53% YoY from $516.0 million in Q1 2025, and down 6.91% on a QoQ basis from $490.4 million in Q4 2025.
Travere Therapeutics (TVTX) Total Liabilities (2011 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 16 years of Total Liabilities data on file, last reported at $456.5 million in Q1 2026.
- Quarterly Total Liabilities fell 11.53% year-over-year to $456.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $456.5 million (down 11.53% YoY) and the FY2025 annual result came in at $490.4 million, down 8.35% from the prior year.
- Total Liabilities retreated to $456.5 million in Q1 2026, from $490.4 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $629.7 million in Q4 2022 to a low of $456.5 million in Q1 2026.
- A 5-year average of $560.3 million and a median of $553.1 million in 2023 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities surged 54.54% — and 2024, when it fell 13.54%.
- Tracing TVTX's Total Liabilities over 5 years: stood at $629.7 million in 2022, then decreased by 6.61% to $588.1 million in 2023, then dropped by 9.02% to $535.0 million in 2024, then decreased by 8.35% to $490.4 million in 2025, then retreated by 6.91% to $456.5 million in 2026.
- The last three Total Liabilities figures came in at $456.5 million (Q1 2026), $490.4 million (Q4 2025), and $465.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | 774.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 774.84 Mn |
| Mar 31, 2026 | 456.46 Mn |
| Dec 31, 2025 | 490.36 Mn |
| Sep 30, 2025 | 465.02 Mn |
| Jun 30, 2025 | 522.56 Mn |
| Mar 31, 2025 | 515.98 Mn |
| Dec 31, 2024 | 535.05 Mn |
| Sep 30, 2024 | 534.86 Mn |
| Jun 30, 2024 | 535.97 Mn |
| Mar 31, 2024 | 589.48 Mn |
| Dec 31, 2023 | 588.10 Mn |
| Sep 30, 2023 | 553.08 Mn |
| Jun 30, 2023 | 619.94 Mn |
| Mar 31, 2023 | 619.09 Mn |
| Dec 31, 2022 | 629.73 Mn |
| Sep 30, 2022 | 625.54 Mn |
| Jun 30, 2022 | 622.78 Mn |
| Mar 31, 2022 | 620.26 Mn |
| Dec 31, 2021 | 474.52 Mn |
| Sep 30, 2021 | 467.71 Mn |